Reporting Ct Scans

1. What body region is being evaluated? (Default: Chest/Abdomen/Pelvis — specify exact order)
2. Was IV contrast administered? If yes, what phase(s)? (Default: With contrast, portal venous phase)
3. Was oral contrast administered? (Default: No)
4. What is the clinical indication? (Default: Replace with actual ICD-10 and clinical question)
5. Are prior CT or cross-sectional studies available for comparison? (Default: No priors)
6. Is the patient on an oncologic treatment protocol requiring RECIST measurement? (Default: No)
7. Is there a known contrast allergy or renal impairment? (Default: No — verify if contrast was given)
8. Is this a trauma/stroke protocol requiring specialized reporting? (Default: Routine diagnostic)

Documents to Request

• CT images in all acquired phases (axial source, coronal/sagittal reformats)
• Requisition with clinical indication and relevant ICD-10 codes
• Prior cross-sectional imaging (CT, MRI) for comparison
• Relevant lab values (creatinine/eGFR if contrast administered)
• Surgical/procedural history pertinent to anatomy
• Oncology staging notes if tumor measurement is requested

Step 1: Technical Assessment

Document acquisition parameters and any limitations affecting interpretation.

Step 2: Systematic Review by Body Region

CT Chest

• Lungs: Evaluate each lobe; nodules by Fleischner 2017 or Lung-RADS; ground-glass opacity, consolidation, interstitial disease pattern
• Airways: Trachea, mainstem bronchi, segmental patency
• Mediastinum: Lymph nodes by station (measure short axis; >10 mm = enlarged); thymic pathology; esophagus
• Pleura: Effusion (measure depth), pneumothorax, thickening, calcification
• Heart/Pericardium: Cardiomegaly, pericardial effusion, coronary calcification
• Chest wall: Rib fractures, soft-tissue masses, breast tissue
• Upper abdomen (included in chest CT): Liver dome, adrenals, upper kidneys

CT Abdomen/Pelvis

• Liver: Size, attenuation, focal lesions (measure and characterize per LI-RADS if cirrhosis), vascular patency
• Gallbladder/Biliary: Wall thickness, stones, duct dilatation (CBD >7 mm, >10 mm post-cholecystectomy)
• Pancreas: Size, duct dilatation (>3 mm), masses, peripancreatic fat stranding
• Spleen: Size (<13 cm craniocaudal), focal lesions
• Adrenals: Nodules (<10 HU = lipid-rich adenoma; >10 HU requires washout study)
• Kidneys: Size, cortical thickness, stones (measure), hydronephrosis grade, masses (Bosniak classification for cysts)
• GI tract: Wall thickening, diverticulitis, appendicitis, obstruction (transition point)
• Mesentery/Retroperitoneum: Lymph nodes (short axis >10 mm), fluid, fat stranding
• Pelvis: Bladder, uterus/ovaries or prostate/seminal vesicles, pelvic lymph nodes
• Vascular: Aortic diameter, aneurysm, dissection, PE (if CT angiography)
• Bones: Lytic/blastic lesions, fractures, degenerative changes
• Soft tissues: Abdominal wall hernias, subcutaneous findings

Step 3: Measurement Standards

All measurements must be reproducible and follow standardized techniques.

For oncologic studies requiring RECIST 1.1, document target lesion measurements in a dedicated table (see measuring-tumor-response skill).

Step 4: Report Structure — ACR-Compliant Format

Header

• Patient demographics, study date/time, accession number
• Examination: specific CPT description (e.g., "CT abdomen and pelvis with IV contrast")
• Clinical indication with ICD-10

Comparison

• List all prior relevant studies with dates and modality

Technique

• Scanner type (if relevant), slice thickness, contrast agent/dose/rate, phases acquired
• Oral contrast administration (type, timing)
• Dose information (CTDIvol, DLP) if available

Findings

• Organize by organ system within the body region
• Each finding: location → description → measurement → comparison to prior → significance
• Use specific attenuation values (HU) when characterizing lesions

Impression

• Numbered, prioritized by clinical significance
• Address the clinical question directly in item #1
• Include ACR Incidental Findings Committee recommendations for incidentalomas
• Specify follow-up modality, timing, and contrast requirement

Step 5: Incidental Findings Management

Apply ACR Incidental Findings Committee white paper recommendations:

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Does the report address the specific clinical question in the impression?
2. Are all incidental findings managed per ACR white paper recommendations?
3. Are measurements reproducible and in the correct axis?
4. Is comparison with prior studies documented with specific dates?
5. Are critical findings communicated and documented per Joint Commission?

Quality Audit

• Technique section includes contrast type, dose, and phases
• Each organ system is explicitly evaluated (no region skipped)
• All measurable lesions include dimensions in millimeters
• Lymph nodes are measured by short-axis diameter
• Incidental findings include specific follow-up per ACR recommendations
• Aortic measurements use outer-wall-to-outer-wall technique
• Adrenal nodules include attenuation values
• Prior comparison studies are listed with exact dates
• Impression items are numbered with most significant first
• Critical findings include communication documentation
• Bosniak classification is applied to renal cystic lesions when appropriate
• Report avoids vague phrases like "clinical correlation recommended" without specific guidance
• Dose information (DLP) is documented when available
• Laterality is explicit for every finding

Guidelines

1. Always specify contrast phase(s) — findings differ dramatically between arterial, venous, and delayed phases.
2. Apply the ACR Incidental Findings Committee recommendations for every incidentaloma; never leave an incidental finding without a management plan.
3. Use Hounsfield unit values when characterizing adrenal, renal, and hepatic lesions — qualitative descriptors alone are insufficient.
4. Measure lymph nodes by short-axis diameter; long-axis measurements overestimate pathologic enlargement.
5. For oncologic patients, state whether RECIST 1.1 measurements are included and reference the dedicated tumor-measurement report.
6. Document dose metrics (CTDIvol and DLP) to support institutional dose-tracking and ALARA compliance.
7. When findings are equivocal, recommend a specific next step (e.g., "dedicated MRI with hepatocyte-specific contrast") rather than "clinical correlation."